Log In
Print this Print this

Aciphex Sprinkle (delayed-release rabeprazole)

  Manage Alerts
Collapse Summary General Information
Company Eisai Co. Ltd.
DescriptionExtended-release 50 mg formulation of rabeprazole, a protein pump inhibitor (PPI)
Molecular Target H+/K ATPase pump
Mechanism of ActionH+/K+ ATPase pump inhibitor
Therapeutic ModalitySmall molecule
Latest Stage of DevelopmentApproved
Standard IndicationGastroesophageal reflux disease (GERD)
Indication DetailsHeal and maintain healing of erosive gastroesophageal reflux disease (GERD) and treat symptomatic non-erosive GERD; Treat gastroesophageal reflux disease (GERD) for 12 weeks in children ages 1-11; Treatment and maintenance treatment of erosive gastroesophageal reflux disease (GERD) and to treat symptomatic GERD
Regulatory Designation
PartnerAvadel Pharmaceuticals plc

 Product Details
 Archive Items are loading loading
Collapse Summary Deals Information
 Deals Details
Get a free BioCentury trial today